WuXi Healthcare Ventures

Overview

WuXi Healthcare Ventures is a cross-border venture capital firm specializing in the life sciences and healthcare sectors. With offices in Shanghai and Cambridge, Massachusetts, the firm focuses on identifying, seeding, and developing innovative life science and healthcare businesses that can benefit from its operational expertise, strategic support, and capital. The firm's mission is to transform patient care by supporting companies with the potential to revolutionize healthcare through transformative therapies. The firm's investment strategy emphasizes cross-border opportunities, particularly between the United States and China, leveraging its deep expertise in both markets. WuXi Healthcare Ventures has invested in a diverse portfolio of companies, including Juno Therapeutics, Agios Pharmaceuticals, Foundation Medicine, Callidus Biopharma, Novira Therapeutics, Twist Biosciences, Hua Medicine, and Adagene. In December 2015, the firm closed its second fund, WuXi Healthcare Ventures II, L.P., with a total of $290 million, exceeding its initial target of $200 million. This fund continues the firm's mission of pursuing cross-border businesses in the life sciences sector. WuXi Healthcare Ventures is known for its commitment to supporting early-stage companies with transformative potential. By combining investment strategies with management expertise, the firm aims to enhance the growth of innovative healthcare companies. Its cross-border approach aligns with macro-trends in both the United States and China, positioning the firm as a significant player in the global life sciences venture capital landscape.

Investment Focus

• Innovative life science and healthcare companies with transformative potential
• Early-stage companies seeking cross-border investment opportunities between the United States and China

Portfolio Companies